Business
First Day of Dealings on AIM
First Day of Dealings on AIM.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 2755Q Shield Therapeutics PLC 26 February 2016 \n\n \nNOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.\n \n \nShield Therapeutics plc\n(\"Shield\" or the \"Company\")\n \nFirst Day of Dealings on AIM\n \nLondon, UK, 26 February 2016. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces that its Ordinary Shares and Warrants were admitted to trading on the AIM market of the London Stock Exchange at 8.00am GMT today. This follows a successful placing raising gross proceeds of £32.5 million by way of a placing and subscription of Ordinary Shares in the capital of the Company and the issue of Warrants to subscribe for Ordinary Shares. On admission the Company will have a market capitalisation of approximately £162 million.\n \nTrading of the Ordinary Shares and Warrants will take place under the symbols \"STX\" and \"STXW\", respectively. \n \nLiberum is acting as Nominated Adviser and Sole Broker to the Company. \n \nIn a separate press release issued today, the Company announced that the European Commission has granted marketing authorisation across all member states for its wholly owned product, Feraccru®, as a treatment for adults with iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD). This approval allows Shield to begin a roll-out of commercialisation in the coming months. \n \nCarl Sterritt, Chief Executive Office of Shield Therapeutics plc, said: \"We are excited to be joining the AIM market today and also extremely pleased to celebrate the approval of our lead drug, Feraccru. The successful completion of our IPO facilitates the commercial launch of Feraccru in Europe, thereby turning us into a revenue-generating specialty pharmaceutical business just five years after we commenced the development of Feraccru. The transaction also enables us to conduct further human trials of Feraccru, positive results from which will facilitate our commercial plans in other indications and markets, including the...